The Europe Recombinant Proteins Market should witness market growth of 10.4% CAGR during the forecast period (2022-2028).
To boost research output and expand their product offerings for income creation, major firms are investing in their R&D initiatives. For instance, in 2021, Merck KGaA expended USD 2.44 billion (EUR 2.4 billion) on research and development, with the majority of the budget going toward healthcare and life sciences.
Such cases are anticipated to strengthen the argument for the expansion of R&D efforts and show the companies' commitment to making a difference for patients. Such corporate activities will probably support industry expansion in the upcoming years. Cloning antibody gene libraries into phage vectors and enabling the phages to infect a host cell line are both steps in the manufacture of recombinant antibodies.
Recombinant antibody development for COVID-19 infection is another area of business involvement. For instance, Sanofi and GSK began a new phase 2b trial with 720 volunteers who were 18 years of age or older in February 2021 to determine the best antigen dosage for the adjuvanted recombinant protein COVID-19 vaccine candidate's phase 3 evaluation.
The Department of Health has been the central government agency primarily in charge of establishing policies for the English healthcare and social care systems. The particular roles & responsibilities of the Department have changed as a result of the 2012 Health and Social Care Act, moving away from direct obligation for delivering the NHS to one that now offers strategic direction, serves as caretaker for the health and care system, evolves national policies, and offer guidance.
The Germany market dominated the Europe Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $170.7 million by 2028. The UK market is anticipated to grow at a CAGR of 9.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 11.2% during (2022-2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End-user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
To boost research output and expand their product offerings for income creation, major firms are investing in their R&D initiatives. For instance, in 2021, Merck KGaA expended USD 2.44 billion (EUR 2.4 billion) on research and development, with the majority of the budget going toward healthcare and life sciences.
Such cases are anticipated to strengthen the argument for the expansion of R&D efforts and show the companies' commitment to making a difference for patients. Such corporate activities will probably support industry expansion in the upcoming years. Cloning antibody gene libraries into phage vectors and enabling the phages to infect a host cell line are both steps in the manufacture of recombinant antibodies.
Recombinant antibody development for COVID-19 infection is another area of business involvement. For instance, Sanofi and GSK began a new phase 2b trial with 720 volunteers who were 18 years of age or older in February 2021 to determine the best antigen dosage for the adjuvanted recombinant protein COVID-19 vaccine candidate's phase 3 evaluation.
The Department of Health has been the central government agency primarily in charge of establishing policies for the English healthcare and social care systems. The particular roles & responsibilities of the Department have changed as a result of the 2012 Health and Social Care Act, moving away from direct obligation for delivering the NHS to one that now offers strategic direction, serves as caretaker for the health and care system, evolves national policies, and offer guidance.
The Germany market dominated the Europe Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $170.7 million by 2028. The UK market is anticipated to grow at a CAGR of 9.5% during (2022-2028). Additionally, The France market would exhibit a CAGR of 11.2% during (2022-2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End-user, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Scope of the Study
By Product
- Growth Factors & Chemokines
- Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors
- Structural Proteins
- Membrane Proteins
- Kinase Proteins & Regulatory Proteins
- Immune Response Proteins
- Others
By End-user
- Pharmaceutical & Biopharmaceutical Companies
- Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
- Others
By Application
- Drug Discovery & Development
- Academic Research Studies
- Biopharmaceutical Production
- Diagnostics
- Biotechnology Research
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Recombinant Proteins Market by Product
Chapter 5. Europe Recombinant Proteins Market by End User
Chapter 6. Europe Recombinant Proteins Market by Application
Chapter 7. Europe Recombinant Proteins Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bio-Techne Corporation
- Thermo Fisher Scientific, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Abcam plc
- Genscript Biotech Corporation
- Miltenyi Biotec B.V. & Co. KG
- Proteintech Group, Inc.
- BPS Bioscience, Inc.
- RayBiotech Life, Inc.
Methodology
LOADING...
Related Reports
From
Recombinant Proteins Global Market Report 2024
- Report
- 200 Pages
- Global
From
Recombinant Proteins Market by Product, Services, End-User, Function - Global Forecast 2025-2030
- Report
- 185 Pages
- Global
From
From
Recombinant Protein Market Report by Product, Application, End User, and Region 2024-2032
- Report
- 137 Pages
- Global
From
This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user access to the product. The product is a PDF. This product is a market research report. This is a site license, allowing all users within a given geographical location of your organization access to the product. The product is a PDF. This product is a market research report. This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF. 
